Comparison of oral piracetam and oral batahistine in treatment of acute vertigo

Comparison of oral piracetam and oral batahistine in treatment of acute vertigo in emergency department patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016011921063N3

Enrollment

Registered

2016-08-28

Start date

2015-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorders of vestibular function. Disorders of vestibular function

Interventions

Intervention 1: Piracetam 800 mg TDS PO. Intervention 2: Betahistin 8 mg TDS PO.

Treatment - Drugs

Piracetam 800 mg TDS PO

Betahistin 8 mg TDS PO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with acute vertigo who are discharged from the ED. Exclusion criteria: Age <18 years ; Prior sensitivity to piracetam or betahistin ; Using other drugs that potentially improve vertigo (antihistamines, anticholinergics, bezodiazepines, ...) ; Peptic ulcer disease history ; Pheochromoytoma disease ; Patients who are not consent to participate in the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vertigo severity. Timepoint: 7 days after treatment. Method of measurement: NRS.	—

Secondary

Measure	Time frame
Nausea intensity. Timepoint: 7 days after treatment. Method of measurement: NRS.;Fatigue intensity. Timepoint: 7 days after treatment. Method of measurement: NRS.;Adverse events. Timepoint: 7 days after treatment. Method of measurement: Adverse event name.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Arhami Dolatabadi

Shahid Beheshti University of Medical Sciences

aliarhami@yahoo.com+98 21 7343 2380

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026